Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Status:
Completed
Trial end date:
2018-04-04
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and tolerability of ruxolitinib in
HIV-positive adults who were virologically suppressed and who were on antiretroviral therapy
(ART).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)